RxDoctor Payments Data

Idania Hidalgo, MD

Family Medicine · Grand Prairie, TXNPI 1154701142

Payments from drug & device makers

$2,767in general payments, 2019–2025

Across 177 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$475
  • AstraZeneca$333
  • Boehringer Ingelheim$299
  • Amarin Pharma, Inc.$289
  • Lilly USA, LLC$181
  • Merck$173
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,755100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,767 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$59,855
Medicare patients
118
Services billed
752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide64$100,240
JardianceEmpagliflozin31$42,947
MounjaroTirzepatide17$36,855
OzempicSemaglutide28$36,819
RybelsusSemaglutide19$35,656
FarxigaDapagliflozin Propanediol25$31,032
LinzessLinaclotide16$24,711
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,739
EliquisApixaban11$15,744
Tresiba Flextouch U-100Insulin Degludec12$11,568
SymbicortBudesonide/Formoterol Fumarate16$5,062
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,719
Atorvastatin Calcium442$3,155
Rosuvastatin Calcium217$2,549
Losartan Potassium230$2,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$181$137,09581 claims
Novo NordiskOzempic, Rybelsus$475$72,47547 claims
Boehringer IngelheimJardiance$299$42,94731 claims
AstraZenecaFarxiga, Symbicort$333$36,09441 claims
AbbVieLinzess, Synthroid$79$26,19236 claims
GSKTrelegy Ellipta$153$16,73923 claims
PfizerEliquis$65$15,74411 claims
Sanofi-aventis U.S. LLCLantus$27$2,07218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Grand Prairie

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →